Subscribe Sign In

Why register?

Home
News
Events
- Find an event
- Live event coverage
Deep Dive
Sales and marketing
Digital
Market Access
Oncology
Patients
R&D
Spotlight On
- Frontiers Health 2021
- The Future of Generics
Advertise

Search

Search

Close

Trending

Why reshoring drug production means embracing continuous manufacturing

Clariness, DailyBreath partner to drive recruitment in asthma trials

J&J says it will stop selling all talc products next year

Cumulus’ gamified dry EEG system tops lab monitoring in trial

Dismay as UK ‘drags its heels’ on AZ’s COVID antibody Evusheld

branded medicines

Progress two years in and opportunities to improve over next three years

Market Access/ Views & Analysis/ Views and analysis

VPAS: Progress two years in and opportunities to improve over next three years

Leela Barham ABPI, branded medicines, Department of Health & Social Care, NHS, VPAS 0 Comment

In the final instalment of our series reviewing the the 2019 Voluntary Scheme for Branded Medicines Pricing and

X

VPAS: Progress two years in and opportunities to improve over next three years

https://pharmaphorum.com/views-analysis-market-access/vpas-progress-two-years-in-and-opportunities-to-improve-over-next-three-years/

Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox

Featured content

How to improve payer engagement with tailored value communication

How to improve payer engagement with tailored value communication

How will NICE fare in a post-Brexit world?

How will NICE fare in a post-Brexit world?

Events

MAPS 2018 EMEA Annual Meeting

MAPS 2018 EMEA Annual Meeting

Cell & Gene Therapy 2018

Cell & Gene Therapy 2018

Patient Engagement Event - a real world snapshot, beyond the talk

Patient Engagement Event - a real world snapshot, beyond the talk

Most popular

Most Viewed

Novartis' Pluvicto gets first European approval in GB
GSK, Sanofi and Haleon 'facing billions of dollars in Zantac liability'
Dismay as UK 'drags its heels' on AZ's COVID antibody Evusheld
AZ and Daiichi's TROP2 ADC shows promise in first-line lung cancer
Eisai steps up beyond-the-pill approach to dementia in Japan

Tweets from @pharmaphorum

Tweets by @pharmaphorum

Advertise
pharmaphorum connect

Contribute
Work for pharmaphorum

About us
Contact us
Privacy policy
Terms & conditions
Cookie Policy

The rights of trade mark owners are acknowledged. pharmaphorum media limited

Website and content copyright © 2009-, pharmaphorum media limited or its licensors; all rights reserved.

© 2022

Powered by WordPress • Themify WordPress Themes

Login

Username or Email Address

Password

Remember Me

Lost your password?

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com